GlassScriptPhysician profile
Amanda Dupuis
NPI 1124690896
$4,219.12
in general payments reported to CMS, 2019-2025
45 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,126 · 2022: $1,389 · 2023: $1,044 · 2024: $337 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,703.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $803.23 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $484.73 | 2021-2025 | Mounjaro, Jardiance, Lyumjev |
| Astrazeneca Pharmaceuticals LP | $281.98 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.70 | 2021-2023 | Jardiance |
| Dexcom, INC. | $245.44 | 2023-2025 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $181.82 | 2021-2023 | Tlando, Nocdurna, Xyosted |
| Xeris Pharmaceuticals, INC. | $171.75 | 2021-2023 | Recorlev, Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $156.51 | 2021-2023 | Unithroid |
| Janssen Pharmaceuticals, INC | $105.81 | 2024 | Invega Sustenna, Invega Trinza, Spravato |
| Insulet Corporation | $103.31 | 2021-2023 | Omnipod |
| Novartis Pharmaceuticals Corporation | $95.88 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.44 | 2022-2023 | |
| Corcept Therapeutics | $81.78 | 2022-2023 | Korlym |
| Amarin Pharma, INC. | $77.55 | 2021-2022 | |
| Ardelyx, INC. | $75.32 | 2022-2023 | Ibsrela |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Dupuis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.